Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASF 1057

Drug Profile

ASF 1057

Alternative Names: ASF-1057; Monooctanoin/nicotinamide cream

Latest Information Update: 01 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astion Pharma A/S
  • Class Nonsteroidal anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Seborrhoeic dermatitis

Most Recent Events

  • 01 Feb 2018 ASF 1057 is still in phase III trials for Seborrhoeic dermatitis in France and Finland (Topical) (EudraCT2007-004649-14)
  • 01 Feb 2018 No recent reports on development identified - Phase-III for Seborrhoeic dermatitis in Denmark, Canada, Sweden and United Kingdom (Topical)
  • 06 Aug 2015 Phase-III development is ongoing in European Union and Canada (EudraCT2006-005637-37, EudraCT2007-004627-38, EudraCT2007-004649-14 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top